Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Sales (2016 - 2025)

Spero Therapeutics' Return on Sales history spans 10 years, with the latest figure at 0.67% for Q4 2025.

  • For Q4 2025, Return on Sales rose 30090.0% year-over-year to 0.67%; the TTM value through Dec 2025 reached 0.12%, up 280.0%, while the annual FY2025 figure was 0.18%, 17223.0% up from the prior year.
  • Return on Sales reached 0.67% in Q4 2025 per SPRO's latest filing, up from 1.36% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 2.2% in Q4 2021 to a low of 300.23% in Q4 2024.
  • Average Return on Sales over 5 years is 28.62%, with a median of 2.5% recorded in 2021.
  • Peak YoY movement for Return on Sales: skyrocketed 35182bps in 2021, then plummeted -30095bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 2.2% in 2021, then dropped by -14bps to 1.89% in 2022, then tumbled by -62bps to 0.72% in 2023, then plummeted by -41568bps to 300.23% in 2024, then surged by 100bps to 0.67% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Return on Sales are 0.67% (Q4 2025), 1.36% (Q3 2025), and 0.14% (Q2 2025).